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Some mycotoxins such as beauvericin (BEA), ochratoxin A (OTA), and zearalenone (ZEA) can cross the blood brain 
barrier, which is why we tested the anti-inflammatory action of a pumpkin carotenoid extract (from the pulp) against these 
mycotoxins and their combinations (OTA+ZEA and OTA+ZEA+BEA) on a blood brain barrier model with co-cultured 
ECV304 and C6 cells using an untargeted metabolomic approach. The cells were added with mycotoxins at a concentration 
of 100 nmol/L per mycotoxin and pumpkin carotenoid extract at 500 nmol/L. For control we used only vehicle solvent 
(cell control) or vehicle solvent with pumpkin extract (extract control). After two hours of exposure, samples were analysed 
with HPLC-ESI-QTOF-MS. Metabolites were identified against the Metlin database. The proinflammatory arachidonic 
acid metabolite eoxin (14,15-LTE4) showed lower abundance in ZEA and BEA+OTA+ZEA-treated cultures that also 
received the pumpkin extract than in cultures that were not treated with the extract. Another marker of inflammation, 
prostaglandin D2-glycerol ester, was only found in cultures treated with OTA+ZEA and BEA+OTA+ZEA but not in the 
ones that were also treated with the pumpkin extract. Furthermore, the concentration of the pumpkin extract metabolite 
dihydromorelloflavone significantly decreased in the presence of mycotoxins. In conclusion, the pumpkin extract showed 
protective activity against cellular inflammation triggered by mycotoxins thanks to the properties pertinent to flavonoids 
contained in the pulp.
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Several mycotoxins such as beauvericin (BEA), 
ochratoxin A (OTA), zearalenone (ZEA), and enniatins 
(ENNs) can cross the blood brain barrier (BBB) and affect 
brain function, mostly through oxidative stress (1–3). Their 
neurotoxic action can mediate mitochondrial dysfunction 
associated with chronic diseases such as Parkinson and 
Alzheimer (4–7).
Applying low mycotoxin concentrations and short time 
of exposure to an in vitro BBB model we wanted to study 
the molecular basis of the early events triggering mycotoxin 
toxicity. Considering that carotenoids have been evidenced 
to protect genes against oxidative action of mycotoxins 
(8–12) and are depleted in Alzheimer’s and Parkison’s 
disease (13, 14), the second aim our study was to establish 
if pumpkin extract protects against BBB damage induced 
by BEA, OTA, and ZEA in differentiated human ECV304 
cells applying the metabolomics approach, which provides 
an insight into how organisms interact with the environment 
(15). It looks into metabolites (intermediates and end 
products of cellular processes) that mediate the body’s 
response to contaminants (metabolome), which are 
identified and quantified by spectrometry.
MATERIALS AND METHODS
Reagents
Cell culture components including Hanks’ Balanced 
Salt Solution (HBSS), Dulbecco’s Modified Eagle Medium 
(DMEM) (1X) supplemented with GlutaMAX, DMEM 
F-12 nutrient mixture [DMEM/F-12 (1:1) (1X)], phosphate 
buffer saline (PBS), foetal bovine serum (FBS), trypsin-
EDTA (0.05 %), streptomycin, and penicillin were all of 
the Gibco brand (Fisher Scientific, Loughborough, UK). 
Dimethyl sulphoxide (DMSO) (99.7 %) was supplied by 
Fisher Bio Reagents (Geel, Belgium) and phenol red by 
Sigma-Aldrich (St. Louis, MO, USA).
Mycotoxin standards – ZEA (≥99 % purity), OTA 
(≥98 % purity), and BEA (≥97 % purity) – were supplied 
by Sigma-Aldrich. Stock solutions at 1 mg/mL of each 
mycotoxin were prepared in methanol and stored in 
darkness at -20 °C until analysis. They were used at a 
working concentration of 100 nmol/L as described 
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elsewhere (10). Methanol was evaporated with nitrogen 
flux and then the standards diluted in DMSO.
Carotenoid extract from pumpkin pulp was provided 
by Nicola Marchetti from the University of Ferrara (16). 
The working concentration of 500 nmol/L is based on beta-
carotene as reference carotenoid to simulate a real-life 
scenario (17).
Solvents for high-performance liquid chromatography 
(HPLC), namely acetonitrile (Optima LC/MS grade) was 
acquired from Fisher Scientific, deionised water (resistivity 
>18 MΩ/cm) was obtained with a Milli-Q SP® Reagent 
Water System (Millipore Corporation, Bedford, MA, USA), 
and formic acid (reagent grade ≥95 %) was supplied by 
Sigma-Aldrich.
Cell culture
The function of the blood-brain barrier was simulated 
with an in vitro model based on human umbilical vein 
endothelial (ECV304) and rat glioma (C6) cell lines (18). 
C6 cells were maintained in DMEM/F-12 medium 
supplemented with 100 U/mL penicillin, 100 mg/mL 
streptomycin, 10 % (v/v) FBS, and 2 mmol/L L-glutamine. 
ECV304 cells were kept in DMEM supplemented with 
100 U/mL penicillin, 100 mg/mL streptomycin, and 10 % 
(v/v) FBS. Culture medium was changed every two days. 
Incubation conditions were: pH 7.4, 37 °C, atmosphere of 
5 % CO2, and constant relative humidity of 95 %.
C6 cells were added to a 24-well PET plate (Falcon) at 
a density of 5×104 cells/mL and incubated for 2–3 h to 
attach. They provide an appropriate environment for 
ECV304 cells to differentiate but make no part of the 
exposure experiment. Then we placed the Millicell-PET 
culture inserts with a polyethylene terephthalate membrane 
(0.4 µm pore size, surface 0.3 cm2; Millipore Corporation, 
Bedford, MA, USA) into the wells and covered them with 
ECV304 cells at a density of 5×104 cells/mL. This ECV304/
C6 co-culture was maintained under incubation conditions 
for 9–10 days until the barrier was formed.
Monolayer integrity checks
From day 4 of co-culture, we measured transepithelial/
transendothelial electrical resistance (TEER) across the 
ECV304 cell monolayer with epithelial voltohmmeter 
(Millicell® ERS-2, Millipore Corporation, Bedford, MA, 
USA) to check BBB integrity (18). The cell monolayer had 
to be preconditioned for the measurements in HBSS for 
30 min by removing the culture medium by aspiration and 
replacing it with 200 µL of HBSS in the apical compartment 
and with 1300 µL in the basal compartment. After TEER 
measurement, HBSS was aspired and replaced with fresh 
C6 cell medium. The TEER value was calculated using the 
following formula:
TEER=(Rtotal-Rcontrol)*A
where Rtotal is the resistance of the cell monolayer, Rcontrol 
the resistance of blank or control inserts, and A is the 
Millicell insert surface. TEER reached its maximum around 
day 9–10 of the experiment. After the exposure, samples 
were collected, HBSS added, and TEER measured again 
to check for barrier damage. We found none regardless of 
treatment.
Monolayer integrity was also verified with phenol red 
permeation on three control inserts. The medium was 
aspired and the inserts washed three times with PBS and 
transferred to a new plate where 1300 µL of PBS were 
added to the basal compartment. The apical compartment 
received 200 µL of a phenol red solution in PBS at a 
concentration of 42 µmol/L, and the plate was incubated at 
37 °C for one hour. Then we collected the content of the 
basal compartment, adjusted pH to 11 with a solution of 
NaOH, and measured the amount of phenol red in the basal 
compartment with a spectrophotometer at 558 nm. The 
finding of <6 % of phenol red in the basal compartment 
evidenced the integrity of the cell monolayer.
BBB exposure experiment
After we confirmed ECV304 cell confluence with TEER 
around day 9 or 10, we could proceed with exposing the 
cells to mycotoxins. Cells were first incubated at 37 °C for 
30 min in 800 µL HBSS added to the basal compartments 
in a new 24-well plate by transferring the ECV304 cell 
monolayer to this new plate to exclude C6 cells from 
exposure (18). This step is important in order to exclude 
metabolites not resulting from ECV304 cell exposure. After 
this preconditioning, the apical compartments of the inserts 
were exposed to a 400 µL mixture of HBSS and OTA, ZEA, 
or BEA alone or OTA+ZEA (1:1) or OTA+ZEA+BEA 
(1:1:1) combinations (100 nmol/L each) with DMSO in the 
final concentration of 0.5 %.
All these mycotoxins were also assayed in parallel with 
the pumpkin extract at the beta-carotene concentration of 
500 nmol/L as reference carotenoid.
In control samples the cells were incubated with 0.5 % 
of DMSO in HBSS. In positive control samples the cells 
were incubated with 500 nmol/L of beta-carotene in HBSS 
diluted with 0.5 % of DMSO. All analyses were done in 
triplicate on cell cultures at passages between the P20 and 
P30.
After 2-hour exposure at 37 °C simulating mycotoxin 
transfer across the BBB, the media of the apical and basal 
compartments were collected separately for each insert/
well and kept at -70 °C until metabolite extraction (Figure 
1).
Metabolite extraction procedure
The basal compartment was selected for metabolite 
extraction because it represents the brain in the model. 
Extracellular metabolites were extracted from the basal 
culture medium according to the Agilent protocol for 
preparation and extraction of biological samples for wide 
coverage in untargeted metabolomics experiments (19). 
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Briefly, samples were defrosted in an ice bath and kept cold 
throughout the extraction procedure. Hydrophilic and lipid 
metabolites were extracted separately. From each sample, 
two aliquots of 320 µL of media each were collected in 
low-binding Eppendorf tubes with 800 µL of MeOH and 
sonicated in an ice/MeOH bath 3–5 times for 1 s each time. 
After sonication, 400 µL of CHCl3 were added and the 
Eppendorf tubes vortexed. Then 400 µL of H2O and 400 µL 
of CHCl3 were added and vortexed. Finally, the Eppendorf 
tubes were centrifuged at 2800 g at 4 °C for 30 min. 
Centrifugation serves to separate the aqueous phase 
containing hydrophilic metabolites at the top layer from 
protein disc in the middle layer and from the organic phase 
with lipid metabolites at the bottom layer. The aqueous and 
organic phase were collected separately and dried. The 
organic phase was dried under the nitrogen stream, and the 
aqueous phase was lyophilised. Finally, the dried aqueous 
and organic phases were reconstituted in 100 µL of 
chromatographic mobile phase A (H2O, 0.1 % formic acid). 
At the end of the process we obtained two replicates of 
aqueous and two replicates of organic phases per basal 
sample. This procedure allows to obtain three biological 
replicates and two technical replicates for each extraction 
type (organic or aqueous) and statistically analyse sample 
data.
Liquid chromatography-electrospray ionisation 
quantitative time of flight-mass spectrometry (LC-ESI-
QTOF-MS)
For chromatographic analysis we used an Agilent 1200-
LC system (Agilent Technologies, Palo Alto, CA, USA) 
equipped with a vacuum degasser, autosampler, and binary 
pump. For the column we used a Luna Omega Polar C18 
(100 mm × 2.1 mm, 3 µm particle size; Phenomenex, 
Torrance, CA, USA). Mobile phase A contained 0.1 % 
formic acid water, and mobile phase B 0.1 % formic acid 
acetonitrile. The injection volume and flow rate were to 
10 µL and 0.3 mL/min, respectively. Samples were injected 
in both positive and negative electrospray ionisation (ESI) 
modes. In the positive mode the injection lasted 20.1 min 
and the gradient programme was as follows: 0–3 min, 95 % 
A; 3–3.5 min, 80 % A; 3.5–6 min, 75 % A; 6–8 min, 35 % 
A; 8–14 min, 20 % A; 14–17 min, 0 % A, and finally 
17.1–20.1 min, 95 % A to re-equilibrate the column. In the 
negative mode, injection lasted 15.5 min, and the gradient 
programme was as follows: 0–1 min, 95 % A; 1–3.5 min, 
50 % A; 3.5–8.5 min, 15 % A; 8.5–9 min, 2 % A; 9–12 min, 
0 % A, and 12.5–15.5 min, 95 % A to re-equilibrate the 
column.
Spectrometry analysis was done with a 6540 Agilent 
Ultra- High-Definition Accurate-Mass QTOF-MS coupled 
to the HPLC part equipped with an Agilent Dual Jet Stream 
for electrospray ionisation (Dual AJS ESI). In the positive 
mode, the following conditions were used: drying gas flow 
(N2) 8.0 L/min; nebuliser pressure 40 psi [275.8 kPa]; gas 
temperature 300 °C; capillary voltage 4000 V; fragmentor 
voltage 100 V, skimmer 65 V; and Oct 1 RF Vpp 750 V. 
The scan range was 50–1500 m/z. Automatic MS/MS 
experiments were carried out using the following collision 
energy values: 10, 20, and 30 eV. In the negative mode the 
conditions were as indicated above, but the capillary voltage 
was 3500 V. Sample data were acquired using the 
MassHunter Workstation software version B.08.00 
(Agilent).
Feature extraction and chromatographic alignment
Total ion chromatograms generated with LC-QTOF-MS 
were processed with the MassHunter Profinder batch 
recursive feature extraction algorithm (Agilent) for small 
molecules/peptides , which, combined with chromatographic 
alignment across multiple data files allows peak finding and 
minimising false positive and negative features.
Statistical analysis
The obtained feature data were then imported to the 
Mass Profiler Professional (MPP) software, version 15.0 
(Agilent) (Figure 1) for statistical data comparison between 
mycotoxin groups, alone or in combination, with or without 
the pumpkin extract, and controls. MPP uses the fold change 
(FC) as the ratio between the groups, and the log ratios are 
calculated for better visualisation of fold changes (Log2FC). 
To determine differences in features between mycotoxin 
and control samples, we used the unpaired t-test. Differences 
in features between mycotoxin groups were tested with the 
one-way analysis of variance (ANOVA). Post-hoc Tukey 
tests were used to identify features differing between each 
mycotoxin group. Two-way ANOVA was used to compare 
mycotoxin and pumpkin extract data. The level of 
significance was set at p<0.05 for all cases using the 
Benjamini-Hochberg multiple testing correction. Finally, 
to identify significant features as compounds we relied on 
the Metlin database, which contains experimental MS/MS 
data for more than 500.000 compounds (20).
Bioinformatics
Once we identified relevant compounds (metabolites), 
we could put to use the Reactome Knowledgebase (21) to 
establish biological processes likely to occur in humans. 
This knowledge base maps molecular features of transport, 
signal transduction, metabolism, DNA replication, and other 
cellular processes to provide a user-friendly tool for 
discovering functional relationships between metabolites.
RESULTS
Differential analysis of metabolite abundances
Metabolomics analysis identified 181 features in the 
basal phase, of which 159 were statistically significant 
176 Alonso-Garrido M, et al. The role of pumpkin pulp extract carotenoids against mycotoxin damage in the blood brain barrier in vitro Arh Hig Rada Toksikol 2021;72:173-181
compared to control. Among these features, 74 were found 
in the samples not treated with the pumpkin extract and 90 
in samples with this extract. Twenty-five features were 
reported in both the organic and aqueous phase in the same 
treatment group. Figure 2 shows the overlapping of 
components between the groups.
The total number of metabolites after removing feature 
repetitions in both the aqueous and organic phases and in 
positive and negative ionisation modes was 46. Of these, 
14 were found in samples with and without pumpkin extract 
(Table 1). In samples treated with pumpkin extract, only 
9-docosene and dihydromorelloflavone were identified 
regard less  o f  the  mycotox in  used ,  bu t  on ly 
dihydromorelloflavone was significantly less abundant in 
these samples than in positive control (control treated with 
pumpkin extract), while it was not found in samples not 
exposed to the extract.
Our findings of antifungal and insecticide compounds 
including dimethylmaleic acid anhydride, dodemorph, 
hexazinone, n-cyclopropylammeline, and nigrifactin (in 
samples not treated with pumpkin extract) and spiromesifen, 
streptonigrin, tioconazole, chloralose, and octadeca-
1(14),15,17-trien-13-one in samples treated with the extract 
point to a prospect of a new line of research and industrial 
application.
Reactome findings
Some of the above 46 metabolites are relevant for 
human metabolic pathways. One of them is leukotriene 
14,15-LTE4, whose abundance was higher than control in 
ZEA and BEA+OTA+ZEA samples not treated with the 
pumpkin extract. It was also identified in BEA samples 
treated with the extract.
Another metabolite is prostaglandin D2-glycerol, found 
in supernatant samples treated with OTA+ZEA and 
BEA+OTA+ZEA combinations but not with the pumpkin 
extract.
Among the fatty acids relevant for human metabolism, 
we found oleic acid in BEA and pumpkin extract samples 
and oleamide in BEA+OTA+ZEA samples (Table 1). 
Phospho-glycerol (PG)(16:0/0:0) was only identified in 
control and ZEA samples. Higher xestoaminol C was found 
in ZEA samples (compared to control). 12,13-DiHOME-d4 
was  more  abundant  in  BEA,  OTA+ZEA, and 
BEA+OTA+ZEA samples. 9-docosene was more abundant 
than in control in all samples save for those treated with 
BEA and OTA (BEA alone, OTA alone, and BEA+OTA+ZEA 
combination).
Mercaptoethanol was found in ZEA and OTA+ZEA 
samples without the pumpkin extract and in OTA+ZEA 
samples with pumpkin extract (Table 1).
Figure 1 Workflow used to assess the metabolic profile of the blood-brain barrier model exposed to mycotoxins with and without 
pumpkin extract. BBB – blood brain barrier; LC-ESI-QTOF-MS – liquid chromatography-electrospray ionisation quantitative time of 
flight-mass spectrometry
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Table 1 Log2FC values of metabolites with significantly changed quantity (p<0.05) compared to respective controls (control containing 
vehicle or vehicle + pumpkin extract) found in the basal media after 2-hour exposure to mycotoxins (100 nmol/L each) with or without 
pumpkin extract (500 nmol/L beta-carotene equivalent)
















12-epi leukotriene B4-d4 18.12
12,13-DiHOME-d4 18.35 18.49 18.34
14,15-LTE4 15.56 15.56 15.56
2-(3-phenylpropyl)pyridine 20.60 19.28 17.84
2-butyl-5-methyl-4-
propyloxazole 15.70 15.49 15.79 15.98 15.88
2-ethyl-5-methylpyridine 19.36
2-propenal, 
3-(1,3-benzodioxol-5-yl)- -19.15 18.18 -19.15 16.59 17.06 1.96 -19.15 1.87
2-protocatechoylphloro 










7-rutinoside -16.32 17.04 17.18 -16.32
6'-hydroxy-2,3,4,5,2',3',4'-
heptamethoxychalcone 17.06






-17.71 -17.71 -17.71 -17.71 -1.68
Dihydromorelloflavone -16.68 -16.18 -16.18 -16.18 -16.18
Dimethylmaleic acid 
anhydride 17.61 18.04 16.06 17.80 17.12 2.05 17.75 1.92
Dodemorph -16.98 18.23 -16.98 -16.82 -16.98 16.30 16.16
Herbacetin 
8-(2'',3'',4''-triacetylxyloside) 15.76
Hexazinone -18.83 -16.76 -16.76 -18.83
Ketophenylbutazone 17.33 17.17
Mercaptoethanol 16.46 19.32 -19.14
Methylmethionine sulfonium 0.73
N-(2'-(4-benzenesulfonamide)-
ethyl) arachidonoyl amine 21.56 21.28 19.63 16.46 17.65 21.39
N-(2'-(4-benzenesulfonamide)-
ethyl) arachidonoyl amine 17.29 17.69 18.54
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DISCUSSION
We identified several metabolites involved in 
inflammatory response, which confirmed the protective 
effect of carotenoids against BBB damage induced by BEA, 
OTA, and ZEA. Thanks to the untargeted metabolomics 
approach, our findings of N-(2’-(4-benzenesulfonamide)-
ethyl) arachidonoyl amine, 12-epi LTB4-d4, 14,15-LTE4, 
and prostaglandin D2-1-glyceryl ester point to a possible 
involvement of the arachidonic acid pathway in human 
blood-brain barrier response following low mycotoxin 
exposure. These metabolites of arachidonic acid oxidation 
activate mediators of wound healing and inflammation 
(22–25) and increase BBB permeability (26), leukotriene 
in particular (27). We believe that cell exposure to ZEA, 
BEA, and OTA in our study, alone or combined, is related 
to lipid peroxidation, as reported elsewhere (28, 29).
Samples exposed to pumpkin extract in our study, in 
turn, had neither leukotriene B4 or prostaglandin D2-1-
glyceryl ester, which points towards flavonoid protection 
against mycotoxin-induced damage (Table 1). The main 
protective mechanism of flavonoids is related to their potent 
free radical scavenging, which lowers the risk of oxidative 
damage and consequently of inflammation (30). This anti-
inflammatory action of flavonoids is related to the inhibition 
of enzymes involved in arachidonic acid metabolism, such 
as cyclooxygenase and 5-lipoxygenase (31).
Interestingly, samples treated with BEA plus pumpkin 
extract still showed 14,15-LTE4 in the basal media but not 
the rest of the abovementioned metabolites. If an interaction 
between BEA’s ionophoric activity, which increases ion 
permeability in biological membranes and reactive oxygen 
species levels (28, 32), and carotenoid instability is the 
reason for increased lipid peroxidation (33) we have not 
observed with other mycotoxins, this is something that 
deserves to be studied in the future. It is also worth 
mentioning that unlike OTA and ZEA, BEA has not been 
regulated in terms of limits and is often detected in cereal-
based food around the world (34).
CONCLUSION
The BBB human in vitro model employed in our study 
points to the involvement of the arachidonic acid pathway 
in mycotoxin action through metabolites like N-(2’-(4-
benzenesulfonamide)-ethyl) arachidonoyl amine, 12-epi 
LTB4-D4, 14,15-LTE4, and prostaglandin D2-1-glyceryl 
ester, which was confirmed by their drop under the influence 
of pumpkin extract. The only exception was concomitant 
exposure to BEA and the extract, in which this protective 
effect was absent.
The limitation of our study was that it yielded low 
metabolite concentrations in the basal samples, which 
means that some metabolites released into media in even 
smaller concentrations may have been overlooked. Future 
research may solve this issue with the use of larger wells 
that can take greater volumes of the media and the use of 
well inserts with a wider surface. Nevertheless, our 
experimental design and statistical analysis, including 
multiple testing corrections, yielded reliable results with 
the detected metabolites.
Future studies of molecular events triggering a 
toxicological pathway after exposure to BEA alone and in 





















Vestitone 7-glucoside 17.07 17.05
Xestoaminol C -16.08 -16.70 -16.08 16.50 -16.72 -16.70
BEA – beauvericin; E – pumpkin extract; OTA – ochratoxin A; ZEA – zearalenone. Positive values indicate higher and negative values 
lower expression compared to control
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combination with other mycotoxins could reveal a possible 
synergy or antagonism with other mycotoxins or dietary 
components.
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Uloga karotenoida iz ekstrakta mesa bundeve u zaštiti od oštećenja krvno-moždane barijere uzrokovane 
mikotoksinima in vitro
Pojedini mikotoksini poput bovericina (BEA), okratoksina A (OTA) i zearalenona (ZEA) prelaze krvno-moždanu barijeru, 
a to je i razlog zbog kojega smo istražili djelovanje ekstrakta karotenoida iz mesa bundeve protiv upalnih procesa izazvanih 
ovim mikotoksinima i njihovim kombinacijama (OTA+ZEA i OTA+ZEA+BEA) na modelu krvno-moždane barijere koji 
se sastojao od kultura stanica ECV304 i C6, oslanjajući se pritom na neciljani metabolomički pristup. Stanice su tretirane 
mikotoksinima u koncentraciji od 100 nmol/L po mikotoksinu odnosno ekstraktom karotenoida u koncentraciji od 
500 nmol/L. Za kontrolu smo upotrijebili samo otapalo (stanična kontrola) odnosno otapalo s bundevinim ekstraktom 
(ekstraktna kontrola). Nakon dva sata tretmana uzorci su analizirani metodom tekućinske kromatografije / masene 
spektrometrije (HPLC-ESI-QTOF-MS), a dobiveni metaboliti identificirani su usporedbom s bazom podataka Metlin. 
Primjena ekstrakta značajno je smanjila količinu metabolita proupalne arahidonske kiseline eoksina (14,15-LTE4) u 
kulturama tretiranima samo zearalenonom odnosno kombinacijom BEA+OTA+ZEA. Drugi upalni biljeg, prostaglandin 
D2-glicerol ester, otkriven je samo u kulturama tretiranima kombinacijama OTA+ZEA odnosno BEA+OTA+ZEA, ali ne 
i u onima koje su usto tretirane bundevinim ekstraktom. Osim toga, u prisutnosti mikotoksina značajno je porasla 
koncentracija metabolita dihidromoreloflavona iz bundevina ekstrakta. Time je taj ekstrakt iskazao zaštitno djelovanje 
protiv stanične upale uzrokovane mikotoksinima zahvaljujući svojstvima flavonoida koji se nalaze u njezinu mesu.
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